» Articles » PMID: 36140470

The Urinary Microbiome: Role in Bladder Cancer and Treatment

Overview
Specialty Radiology
Date 2022 Sep 23
PMID 36140470
Authors
Affiliations
Soon will be listed here.
Abstract

Commensal microbes have increasingly been found to be involved in the development and progression of cancer. The recent discovery of the urinary microbiome bolstered the notion that microbes might play a role in bladder cancer. Although microbial involvement in bladder neoplastic transformation and metastatic progression, except schisto somiasis, has not been established, accumulating research suggests that dysbiosis of the urinary microbiome can produce a chronically inflammatory urothelial microenvironment and lead to bladder cancer. In this review, we describe how the urinary microbiome might facilitate the development of bladder cancer by altering the host immune system and the kind of cytokines that are directly involved in these responses. We investigated the therapeutic possibilities of modulating the urinary microbiome, including immune checkpoint therapy. The responsiveness of patients to intravesical Bacillus Calmette-Guerin therapy was evaluated with respect to microbiome composition. We conclude by noting that the application of microbes to orchestrate the inflammatory response in the bladder may facilitate the development of treatments for bladder cancer.

Citing Articles

Schistosomiasis-Microbiota Interactions: A Systematic Review and Meta-Analysis.

Afful P, Abotsi G, Adu-Gyamfi C, Benyem G, Katawa G, Kyei S Pathogens. 2024; 13(10).

PMID: 39452777 PMC: 11510367. DOI: 10.3390/pathogens13100906.


Squamous cell carcinoma of the urinary bladder in patients with chronic spinal cord injury: A case series.

Levien P, Pannek J, Janzen J, Wollner J Spinal Cord Ser Cases. 2024; 10(1):67.

PMID: 39277574 PMC: 11401855. DOI: 10.1038/s41394-024-00680-z.


A review of urinary bladder microbiome in patients with bladder cancer and its implications in bladder pathogenesis.

Stamatakos P, Fragkoulis C, Zoidakis I, Ntoumas K, Kratiras Z, Mitsogiannis I World J Urol. 2024; 42(1):457.

PMID: 39073494 DOI: 10.1007/s00345-024-05173-0.


Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer.

Totonji S, Ramos-Triguero A, Willmann D, Sum M, Urban S, Bauer H Cancers (Basel). 2024; 16(8).

PMID: 38672614 PMC: 11049522. DOI: 10.3390/cancers16081532.


The Role of Metabolomics and Microbiology in Urinary Tract Infection.

Zheng H, Wang C, Yu X, Zheng W, An Y, Zhang J Int J Mol Sci. 2024; 25(6).

PMID: 38542107 PMC: 10969911. DOI: 10.3390/ijms25063134.


References
1.
Liu J, Wang L, Wang T, Wang J . Expression of IL-23R and IL-17 and the pathology and prognosis of urinary bladder carcinoma. Oncol Lett. 2018; 16(4):4325-4330. PMC: 6126236. DOI: 10.3892/ol.2018.9145. View

2.
Eruslanov E, Neuberger M, Daurkin I, Perrin G, Algood C, Dahm P . Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer. 2011; 130(5):1109-19. DOI: 10.1002/ijc.26123. View

3.
Galsky M, Wang H, Hahn N, Twardowski P, Pal S, Albany C . Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol. 2017; 73(5):751-759. DOI: 10.1016/j.eururo.2017.12.001. View

4.
Pederzoli F, Ferrarese R, Amato V, Locatelli I, Alchera E, Luciano R . Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients. Eur Urol Oncol. 2020; 3(6):784-788. DOI: 10.1016/j.euo.2020.04.002. View

5.
Raziuddin S, Masihuzzaman M, Shetty S, Ibrahim A . Tumor necrosis factor alpha production in schistosomiasis with carcinoma of urinary bladder. J Clin Immunol. 1993; 13(1):23-9. DOI: 10.1007/BF00920632. View